| Identification | Back Directory | [Name]
Troriluzole | [CAS]
1926203-09-9 | [Synonyms]
BHV-4157
Troriluzole
Trigriluzole
Glycinamide, glycylglycyl-N2-methyl-N-[6-(trifluoromethoxy)-2-benzothiazolyl]- | [Molecular Formula]
C15H16F3N5O4S | [MDL Number]
MFCD32204755 | [MOL File]
1926203-09-9.mol | [Molecular Weight]
419.38 |
| Chemical Properties | Back Directory | [density ]
1.518±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 50 mg/mL (119.22 mM; Need ultrasonic) | [form ]
Solid | [pka]
8.88±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Troriluzole, a third-generation, tripeptide proagent of Riluzole (HY-B0211), is an orally active glutamate modulator. Troriluzole reduces synaptic glutamate level and increases the synaptic glutamate absorption. Troriluzole has the potential for Alzheimer disease and generalized anxiety disorder (GAD)[1][2]. | [References]
[1] Schanzer B, et al. Novel investigational therapeutics for generalized anxiety disorder (GAD). Expert Opin Investig Drugs. 2019 Nov;28(11):1003-1012. DOI:10.1080/13543784.2019.1680638
[2] Huang LK, et al. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci. 2020 Jan 6;27(1):18. DOI:10.1186/s12929-019-0609-7 |
|
|